Pfizer and Merck have slightly lowered the prices of their respective Paxlovid and molnupiravir COVID-19 treatments in China, local media reported on Tuesday citing pricing information published by the province of Jiangsu.
Tag Archive for: Paxlovid
The current emergency use authorization (EUA) for Pfizer’s COVID-19 antiviral pill for high-risk adolescents will continue to remain in effect even if it receives full approval for use in some adults.
The comments were made in the FDA’s briefing documents ahead of a meeting of the agency’s external advisers on Thursday.
Japan’s Shionogi & Co. Ltd. believes its COVID-19 pill will easily garner $2 billion in annual sales if it secures U.S. approval, which the company expects to receive in late 2024, its chief executive said.
Merck & Co. Inc. said on Tuesday its COVID-19 pill was not effective at cutting the risk of coronavirus infections in people living with someone infected with the virus.
The U.S. government on May 11 will end the COVID-19 Public Health Emergency (PHE) that allowed millions of Americans to receive vaccines, tests, and treatments at no cost during the pandemic.
Pfizer Inc. on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment in 2023, intensifying investor concerns over demand for the products as governments cut orders and work through inventories.
In an expansion of the company’s “An Accord for a Healthier World” program, which is aimed at increasing access to innovative treatments in some of the world’s poorest countries, Pfizer said it will now offer a total of 500 products.
Chinese authorities have acknowledged that supplies of Paxlovid are still insufficient to meet demand, even as Pfizer CEO Albert Bourla said last week that thousands of courses of the treatment were shipped to the country last year and in the past couple of weeks millions more were shipped.
Pfizer Inc. is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday.
